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Purpose: To evaluate the efficacy of vitrectomy for persistent diabetic macular edema after laser 
photocoagulation or intravitreal triamcinolone injections and to determine the demographic and ocular factors 
that influence functional and anatomical outcomes.
Methods: We retrospectively evaluated 55 eyes (51 patients) that had persistent diffuse macular edema 
after laser photocoagulation or intravitreal triamcinolone injections. We compared preoperative and 
postoperative best corrected visual acuity and macular thickness by Optical Coherence Tomography and 
investigated factors including patient's age, presence of vitreomacular traction, grade of diabetic retinopathy, 
and intraoperative internal limiting membrane removal that may influence the surgical results. 
Results: The mean preoperative BCVA (log MAR) was 0.91±0.40 (0.8-1.2). The BCVA improved to 0.72±
0.39 (0.3-1.2). The mean preoperative macular thickness was 440±130 (202-805) µm and the mean 
macular thickness decreased to 306±97 (136-580) µm postoperatively. The eyes showed statistically 
significant improvement in BCVA and central macular thickness (p<0.001). Preoperative better BCVA was 
associated with an improved postoperative visual acuity. (p=0.04). No other covariates were found to be 
statistically significant factors for prognosis of postoperative BCVA.
Conclusions: In eyes with persistent diabetic macular edema after laser or IVTA injections, vitrectomy was 
effective for decreasing macular thickness and improvement of vision. The visual improvement after 
vitrectomy was associated with the preoperative better BCVA.
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For eyes with long-standing diabetic macular edema 
(DME) that persists or recurs after laser photocoagulation or 
intravitreal triamcinolone injection (IVTA), limited treatment 
benefits are expected. This is because of the structural 
damage caused by chronic macula edema and the underlying 
diabetic retinopathy. Several retrospective studies showed that 
vitrectomy leads to reduction of central macular thickness 
(CMT) in most cases and improvement of visual acuity in 
43-69% of study eyes.
1-4 Stolba et al performed a prospective 
study and reported, that vitrectomy with internal limiting 
membrane (ILM) peeling was found to be superior to 
observation alone; in addition, an interaction with therapy 
time was significant and had a negative impact on vision, 
confirming a decrease of vision with time in the control 
group.
5 However, there are many opinions regarding the 
effect of vitrectomies on eyes without vitreomacular traction. 
Tachi and Ogino reported a positive effect of vitrectomy on 
macular edema in eyes without any evidence of vitreomacular 
traction.
6 On the other hand, Shah et al reported that the 
visual benefit of vitrectomy is limited to eyes with signs of 
macular traction.
7 It is important for the surgeon to determine 
the factors that might influence surgical outcome so that 
patients are chosen for the procedure that they can get benefit 
from. Therefore, we made the hypothesis that vitrectomy was 
effective for decreasing macular thickness and improvement 
of vision for eyes with persistent DME after laser 
photocoagulation or IVTA, and evaluated the possible 
preoperative and intraoperative factors that might influence 
surgical outcomes.
Materials and Methods
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Variable
Gender M:F 28:23
Age  59±10 (41-76)
HbA1c (%) 6.66±0.70 
(5.9-7.9)
Hypertension 22 (40%)
Stage of retinopathy, severe NPDR
*:PDR
† 39:16
Preoperative macular laser treatment 34 (62%)
Preoperative IVTA
‡ 27 (49%)
Preoperative lens status, pseudophakic:phakic 13:42
Values represent the mean±SD.
NPDR
* : Nonproliferative diabetic retinopathy.
PDR
†: Proliferative diabetic retinopathy.
IVTA
‡: Intravitreal triamcinolone injection.
Table 1. Characteristics of study eyes hospitals by 3 surgeons between February 2004 and February 
2006. Fifty-five eyes (51 patients) with DME that had 
recurrent or persistent macular edema after laser or 
intravitreal triamcinolone injections were included in this 
study. Inclusion criterion was a BCVA of 0.3 or worse in 
Log MAR units because of recurrent or persistent macular 
edema secondary to DMR in spite of laser photocoagulation 
or intravitreal triamcinolone injections. The period of DME 
since the last laser photocoagulation or intravitreal 
triamcinolone injections was at least 3 months. Exclusion 
criteria were significant macular ischemia defined as enlarged 
perifoveal capillary loss (>1000 µm) by fluorescein 
angiography, the focal macular edema due to focal leakage 
from microaneurysm, and other macular pathology such as 
age related macula degeneration, retinal vascular occlusive 
diseases, combined optic neuropathy, glaucoma including 
neovascular glaucoma, vitreous hemorrhage or tractional 
retinal detachments secondary to diabetic retinopathy. All 
patients provided written informed consent. All of the 
patients were followed for at least 6 months with a mean 
follow-up period of 8.3±7.0 (6-26) months. The BCVA for 
Snellen chart, lens status, retinopathy stage, and the history 
of laser photocoagulation and/or IVTA, fundus photography, 
fluorescein angiography, and OCT (Humphrey model 3000; 
Humphrey Instruments, San Leandro, CA) were assessed 
preoperatively and at a mean of 3 month intervals during the 
follow-up period. OCT was performed six 6 mm radial scans 
centered at the patient's fixation point at 30 degree intervals. 
Retinal thickness was computed using the OCT mapping 
software. The preoperative and postoperative BCVA were 
converted to log MAR for statistical analysis. An 
improvement in visual acuity was defined as two or more 
improved lines of BCVA. All eyes had standard 20 gauze 
vitrectomy. The paired t-test was used for comparison of 
preoperative and postoperative visual acuities and central 
fovea thickness. Multivariate linear regression was performed 
to evaluate the possible association of age, HbA1C level, 
preoperative BCVA, preoperative central macular thickness 
(CMT), phakic status, presence of vitreoretinal traction 
(presence of epiretinal membrane or taut posterior hyaloid), 
diabetic retinopathy stage, history of grid laser 
photocoagulation and IVTA or both, preoperative BCVA, and 
intraoperative internal limiting membrane removal with a 
change in postoperative BCVA. To rule out the possible 
effect of postoperative cataract progression on postoperative 
BCVA, we compared the results of eyes that were already 
pseudophakic with eyes that had concomitant cataract 
surgery.
Results
The demographic characteristics of the patients including 
age, gender, HbA1C level, diabetic retinopathy stage, 
previous laser or IVTA, presence of systemic hypertension 
are shown in Table 1.
The mean preoperative BCVA (log MAR) was 0.91±0.40 
(0.8-1.2). The BCVA improved to 0.72±0.39 (0.3-1.2) 
postoperatively. The mean postoperative visual acuity was 
significantly better than the preoperative visual acuity 
(p<0.001). The improvement of visual acuity was more than 
two lines in 27 (49%) eyes. The preoperative macular 
thickness was 440±130 µm (range; 202-805 µm) and the 
macular thickness significantly decreased to 306±97 µm 
(range; 136-580 µm) postoperatively (p<0.001). Thirty-four 
(62%) eyes had concomitant cataract surgery during the 
vitrectomy procedure. Thirteen eyes (24%) had already 
undergone cataract surgery before the vitrectomy. Cataract 
surgery was performed in 3 (5%) eyes during the follow-up 
period. The numbers of eyes that had laser photocoagulation 
or IVTA are shown in Table 1. Seventeen (31%) eyes had 
both laser photocoagulation and IVTA. Two eyes had IVTA 
twice. Seventeen eyes (31%) had previous pan retinal 
photocoagulation (PRP). Thirty-two (58%) eyes had 
vitreomacular traction (presence of epiretinal membrane or 
taut posterior hyaloid, p=0.512). The internal limiting 
membrane was peeled in 22 (40%) eyes and indocyanine 
green (ICG, 0.25%) dye was used in 19 eyes. Intraoperative 
ILM peeling did not affect the postoperative BCVA 
(p=0.430). The concomitant cataract surgery with vitrectomy 
had better postoperative BCVA with marginal statistical 
significance (p=0.06, paired t test). Better preoperative 
BCVA was associated with a better postoperative BCVA 
(p=0.04). No other covariates were found to be statistically 
significant factors associated with postoperative BCVA 
improvement (Table 2).
During the follow-up period, deterioration of BCVA was 
noted in 6 eyes (11%). The causes for deterioration of BCVA 
were vitreous hemorrhage due to progression of diabetic 
retinopathy in 2 eyes and persistent macular edema in 4 eyes. 
Two eyes had increased intraocular pressure which 
was controlled with topical medications. No eye had 
complications such as iris neovascularization, retinal 
detachments during the follow-up period.Kor J Ophthalmol Vol.21, No.3, 2007
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Sig. Exp (B) 95.0% C.I. for EXP (B)
   Lower Upper
Age (yrs) .798 1.009 .940 1.084
Hypertension (yes vs no) .241 2.285 .575 9.084
HbA1c .465 .779 .400 1.520
DMR
* grade .391 4.206 .158 111.826
Vitreomacular traction (yes vs no) .512 .513 .069 3.784
Preoperative BCVA
† .046 6.732 1.034 43.851
Preoperative CMT
‡ .738 1.001 .996 1.006
Laser vs IVTA vs both .525 .544 .083 3.556
ILM
§ removal (yes vs no) .430 .580 .149 2.249
Constant .610 .154   
DMR
* : diabetic retinopathy.
BCVA
†: Best corrected visual acuity.
CMT
‡: Central macular thickness.
ILM
§ : Internal limiting membrane.
Table 2. Logistic regression analysis results: Dependent variables: Postoperative visual acuity improvement
Fig. 1. Pre- and postoperative best corrected visual acuity (Log
MAR).
BCVA: Best corrected visual acuity.
Discussion
Diabetic macular edema (DMR) is a major cause of visual 
loss in diabetic patients.
8 The natural history of DME is 
progressive visual loss with >50% of patients losing more 
than 2 lines of visual acuity within 2 years.
9 The Early 
Treatment Diabetic Retinopathy Study (ETDRS) showed that 
laser photocoagulation stabilized vision and reduced the risk 
of visual loss by 50%.
10 But only 3% of patients had 
improved by three or more lines of vision by the end of 
study. Recently, improvement of macular edema and visual 
acuity after intravitreal triamcinolone injections (IVTA) on 
DME has been reported.
11-13
However, laser photocoagulation and IVTA results were 
not satisfactory in many cases because of common recurrent 
or persistent macular edema. The efficacy of pars plana 
vitrectomy (PPV) has been reported for the treatment of 
diffuse DME with taut posterior hyaloid. Since Lewis et al 
reported that PPV was effective for treating DME with 
thickened and taut posterior hyaloid that did not respond to 
laser treatment, many reports showed that vitrectomy resulted 
in a decrease of macular edema and improvement of visual 
acuity.
14,15 Although less encouraging results were anticipated 
due to photoreceptor damage caused by chronic macula 
edema and the underlying diabetic retinopathy, our study 
results showed that the mean postoperative BCVA was 
significantly better than the preoperative BCVA (p<0.001). In 
addition, more than two lines of BCVA improvement were 
achieved in 27 (49%) eyes. These findings are consistent with 
the aforementioned studies and show that vitrectomy can help 
restore macular structure as well as improve visual acuity for 
eyes with persistent DME after laser photocoagulation or 
IVTA. For eyes without taut posterior hyaloid and in eyes 
with posterior vitreous detachments, the efficacy of 
vitrectomy is controversial.
6,7 Our study showed that the 
presence of vitreomacular traction (presence of epiretinal 
membrane or taut posterior hyaloid) did not affect the 
surgical results (p>0.05). This finding suggests that we can 
expect a decrease in macular edema and improvement of 
visual acuity even in the eyes without vitreomacular traction. 
The correlation of preoperative BCVA and postoperative 
visual acuity improvement was statistically significant 
(p=0.04). This fact is implying that preoperative degree of 
photoreceptor cell dysfunction by chronic macular edema and 
underlying diabetic retinopathy is important for postoperative 
visual improvement. And early surgical intervention may be 
helpful for eyes with chronic DME that persists after laser 
photocoagulation and IVTA. Another controversial subject is 
removal of ILM during vitrectomy. Removal of the ILM may 
have the additional benefit of preventing later epiretinal 
membrane formation by removing the scaffold for 
proliferating cells. 
n=55Fig. 3. Preoperative OCT scan (A) shows diffuse macular thickening of 505 µm. Postoperative OCT scan (B) performed 3 months 
after vitrectomy shows reduction in macular thickness (202 µm) and a restoration of the foveal contour. 
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Fig. 2. Fundus photography and fluorescein angiography of 60 year old female patient. Preoperative fundus photography (A) shows
hard exudates within the macula and diffuse macular edema, and fluorescein angiography (C) shows diffuse intraretinal and subretinal
leakage of fluorescein dye. Fundus photography (B) and fluorescein angiography (D) taken at three month after the operation show
resolved macular edema and reduced fluorescein leakage. Visual acuity improved from 0.7 to 0.5 (LogMAR). 
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Several reports showed that vitrectomy with ILM removal 
has a better anatomical as well as functional results.
15,16 
However, for eyes with chronic diffuse DME, there are 
concerns for further photoreceptor damage in an already 
damaged macula by removing ILM as well as the possible 
ICG dye toxicity during the ILM removal.
17-19 Yamamoto et 
al reported that the ILM does not have to be removed to treat 
eyes with DME.
20 Our study showed that ILM removal did 
not affect either the anatomical or the functional surgical 
outcomes. Cataract progression after vitrectomy may 
influence the postoperative BCVA. And our study result 
showed that eyes with concomitant cataract surgery with 
vitrectomy had better postoperative BCVA but with marginal 
statistical significance (p=0.06). This result may have been 
influenced by the small number of patients studied. 
Limitations of the present study include relatively small study 
numbers that may influence the statistical results and lack of 
a control group. In conclusion, our study provides evidence 
that vitrectomy can be an effective method to restore macular 
structure and may improve visual acuity for eyes with 
persistent DME after laser photocoagulation or IVTA even in 
eyes without vitreomacular traction. Preoperative BCVA was 
significantly associated with postoperative visual acuity. An 
additional positive effect of ILM removal on postoperative 
BCVA was not significant. A larger prospective case series 
is needed with longer observation time to further evaluate the 
effect of vitrectomy on persistent diffuse DME after laser or 
IVTA.
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